Top

Published in:

Open Access 01-12-2018 | Research article

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis

Authors: Hyung Joon Joo, Han Saem Jeong, Hyungdon Kook, Seung Hun Lee, Jae Hyoung Park, Soon Jun Hong, Cheol Woong Yu, Do-Sum Lim

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Abstract

Background

There have been limited data on the impact of hyperuricemia on long-term clinical outcomes after percutaneous coronary intervention (PCI) for in-stent restenosis (ISR).

Methods

From January 2009 to July 2015, 317 patients who underwent repeat PCI for ISR were divided into two groups: patients with normal serum uric acid (UA) levels (normal UA group) and patients with higher serum UA levels (higher UA group). The higher UA group included patients with serum UA levels > 6.8 mg/dL or patients who were taking anti-hyperuricemic medication.

Results

During a median follow-up period of 1088 days, the cumulative incidence rates of major adverse event (MAE), including a composite of all-cause death, non-fatal myocardial infarction, and any revascularization, were similar between the two groups (higher UA 36.4% vs. normal UA 29.9%, p = 0.389, log-rank p = 0.367). Follow-up angiographic data showed similar outcomes of late lumen loss (0.8 ± 0.9 mm vs. 0.8 ± 1.1 mm, p = 0.895) and binary restenosis rate (28.1% vs. 34.7%, p = 0.622). Multivariate Cox regression analysis indicated higher levels of low-density lipoprotein cholesterol (hazard ratio [HR] 1.011, 95% confidence interval [CI] 1.003–1.019, p = 0.006) and lower left ventricular ejection fraction (HR 0.972, 95% CI 0.948–0.996, p = 0.022), but not UA levels, to be the independent risk predictors of MAE.

Conclusion

Hyperuricemia is not associated with poor clinical outcomes after repeat PCI for ISR lesions.

Available only for authorised users

Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998–1008.CrossRefPubMed

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–23.CrossRefPubMed

Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, Ellis SG, Coleman P, Hill C, Shi C, et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47(7):1350–5.CrossRefPubMed

Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109(16):1942–7.CrossRefPubMed

Turco MA, Ormiston JA, Popma JJ, Hall JJ, Mann T, Cannon LA, Webster MW, Mishkel GJ, O'Shaughnessy CD, McGarry TF, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberte stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2008;1(6):699–709.CrossRefPubMed

Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G, Investigators ES. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362(9390):1093–9.CrossRefPubMed

Alfonso F, Perez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, Garcia-Touchard A, Marti V, Lozano I, Angel J, Hernandez JM, et al. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [restenosis intra-stent: balloon angioplasty versus drug-eluting stent]). JACC Cardiovasc Interv. 2012;5(7):728–37.CrossRefPubMed

Mehilli J, Byrne RA, Tiroch K, Pinieck S, Schulz S, Kufner S, Massberg S, Laugwitz KL, Schomig A, Kastrati A, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (intracoronary stenting and angiographic results: drug eluting stents for in-stent restenosis 2) study. J Am Coll Cardiol. 2010;55(24):2710–6.CrossRefPubMed

Alfonso F, Cequier A, Angel J, Marti V, Zueco J, Bethencourt A, Mantilla R, Lopez-Minguez JR, Gomez-Recio M, Moris C, et al. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. Am Heart J. 2006;151(3):681. e681-681 e689CrossRefPubMed

10.

Zahn R, Hamm CW, Schneider S, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, et al. Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher stent registry. J Interv Cardiol. 2010;23(1):18–25.CrossRefPubMed

11.

Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schomig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113(19):2293–300.CrossRefPubMed

12.

Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–907.CrossRefPubMed

13.

Hsieh IC, Chen CC, Hsieh MJ, Yang CH, Chen DY, Chang SH, Wang CY, Lee CH, Tsai ML. Prognostic impact of 9-month high-sensitivity C-reactive protein levels on long-term clinical outcomes and in-stent restenosis in patients at 9 months after drug-eluting stent implantation. PLoS One. 2015;10(9):e0138512.CrossRefPubMedPubMedCentral

14.

Jiang H, Liu W, Liu Y, Cao F. High levels of HB-EGF and interleukin-18 are associated with a high risk of in-stent restenosis. Anatol J Cardiol. 2015;15(11):907–12.CrossRefPubMedPubMedCentral

15.

Jing XD, Wei XM, Deng SB, Du JL, Liu YJ, She Q. The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta. 2015;446:248–52.CrossRefPubMed

16.

Liang S, Aiqun M, Jiwu L, Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol Res. 2016;64(2):424–30.CrossRefPubMed

17.

Mene P, Punzo G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J Hypertens. 2008;26(11):2085–92.CrossRefPubMed

18.

Battelli MG, Polito L, Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. Atherosclerosis. 2014;237(2):562–7.CrossRefPubMed

19.

Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–46.CrossRefPubMed

20.

Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104.CrossRefPubMed

21.

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and nutrition examination survey. JAMA. 2000;283(18):2404–10.CrossRefPubMed

22.

Turak O, Canpolat U, Ozcan F, Mendi MA, Oksuz F, Isleyen A, Gurel OM, Cay S, Aras D, Aydogdu S. Usefulness of preprocedural serum uric acid level to predict restenosis of bare metal stents. Am J Cardiol. 2014;113(2):197–202.CrossRefPubMed

23.

Yin Z, Fang Z, Yang M, Du X, Nie B, Gao K. Predictive value of serum uric acid levels on mortality in acute coronary syndrome patients with chronic kidney disease after drug-eluting stent implantation. Cardiology. 2013;125(4):204–12.CrossRefPubMed

24.

Wilcox WR, Khalaf A, Weinberger A, Kippen I, Klinenberg JR. Solubility of uric acid and monosodium urate. Med Biol Eng. 1972;10(4):522–31.CrossRefPubMed

25.

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–51.CrossRefPubMed

26.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed

27.

Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation. 1999;100(18):1872–8.CrossRefPubMed

28.

Li M, Hu X, Fan Y, Li K, Zhang X, Hou W, Tang Z. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep. 2016;6:19520.CrossRefPubMedPubMedCentral

29.

Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation and vascular disease. Semin Nephrol. 2005;25(1):39–42.CrossRefPubMed

30.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.CrossRefPubMed

31.

Niccoli G, Conte M, Cosentino N, Todaro D, Brugaletta S, Montone RA, Minelli S, Fracassi F, Galiffa V, Leone AM, et al. Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. J Invasive Cardiol. 2011;23(1):16–20.PubMed

32.

Lee S, Yoon CH, Oh IY, Suh JW, Cho YS, Cho GY, Chae IH, Choi DJ, Youn TJ. Angiographic patterns of restenosis with 2nd generation drug-eluting stent: comparative analysis from a 10-year single-center experience. Int Heart J. 2015;56(1):6–12.CrossRefPubMed

33.

Kitahara H, Kobayashi Y, Takebayashi H, Nakamura Y, Kuroda N, Miyazaki A, Haruta S, Komuro I. Angiographic patterns of restenosis after sirolimus-eluting stent implantation. Circ J. 2009;73(3):508–11.CrossRefPubMed

34.

Corbett SJ, Cosgrave J, Melzi G, Babic R, Biondi-Zoccai GG, Godino C, Morici N, Airoldi F, Michev I, Montorfano M, et al. Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. Eur Heart J. 2006;27(19):2330–7.CrossRefPubMed

35.

Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y, Domei T, Soga Y, Hyodo M, Shirai S, et al. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation- an optical coherence tomography study. Circ J. 2017;81(4):450–7.CrossRefPubMed

36.

Yamashita K, Ochiai M, Yakushiji T, Ebara S, Okabe T, Yamamoto MH, Saito S, Hoshimoto K, Isomura N, Araki H, et al. Repeat drug-eluting stent implantation for in-stent restenosis: first- or second-generation stent. J Invasive Cardiol. 2012;24(11):574–8.PubMed

37.

Almalla M, Pross V, Marx N, Hoffmann R. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. Coron Artery Dis. 2012;23(7):492–6.CrossRefPubMed

38.

Zhu W, Li J, Luo H, Wang G, Hua Q. Comparison of 2-year outcomes of repeated second-generation drug-eluting stent implantation for focal-type versus nonfocal-type in-stent restenosis. Coron Artery Dis. 2015;26(7):587–91.CrossRefPubMed

39.

Naganuma T, Latib A, Costopoulos C, Oreglia J, Testa L, De Marco F, Candreva A, Chieffo A, Naim C, Montorfano M, et al. Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. EuroIntervention. 2016;11(9):989–95.CrossRefPubMed

40.

Zhao L, Zhu W, Zhang X, He D, Guo C. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord. 2017;17(1):16.CrossRefPubMedPubMedCentral

41.

Lee JM, Rhee TM, Hahn JY, Hwang D, Park J, Park KW, Kim HL, Kim SH, Chae IH, Doh JH, et al. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: patient-level pooled analysis of Korean multicenter in-stent restenosis registry. Int J Cardiol. 2017;230:181–90.CrossRefPubMed

42.

Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M, Osue T, Taniguchi Y, Iwasaki M, Nishio R, Kinutani H, et al. The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention. 2016;12(11):e1366–74.CrossRefPubMed

43.

Bastante T, Rivero F, Benedicto A, Cuesta J, Alfonso F. Recurrent Neoatherosclerosis after Bioresorbable vascular scaffold treatment of in-stent restenosis. JACC Cardiovasc Interv. 2015;8(9):1264–5.CrossRefPubMed

Title: Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
Authors: Hyung Joon Joo
Han Saem Jeong
Hyungdon Kook
Seung Hun Lee
Jae Hyoung Park
Soon Jun Hong
Cheol Woong Yu
Do-Sum Lim
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-018-0840-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Profile of patients with hypertensive urgency and emergency presenting to an urban emergency department of a tertiary referral hospital in Tanzania

Acute coronary syndrome secondary to allergic coronary vasospasm (Kounis Syndrome): a case series, follow-up and literature review

Simplification and optimization of transcatheter aortic valve implantation – fast-track course without compromising safety and efficacy

Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds

Cytochrome P450 family 4 subfamily F member 2 (CYP4F2) rs1558139, rs2108622 polymorphisms and susceptibility to several cardiovascular and cerebrovascular diseases

Native valve endocarditis due to Escherichia coli infection: a case report and review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page